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Implants aim to substitute or to support in case of own
tissue deficiency and therefore played an increasing role for
pelvic floor reconstruction in last decades. Several scientific
theories (i.e., integral theory) and promising results from
tertiary centers promoted the rising application of alloplastic
materials [1]. With industry being deeply engaged in this
field from the very beginning a huge variety of products was
launched over the years and was approved due to simple
administrative procedures (US: 510K; Germany/EU: medical
product law and device regulation). Aggressive marketing
helped to spread these products around the world, since there
are millions of female patients in our aging society suffering
from incontinence and pelvic floor prolapse. In a Public
Health Notification (PHN), from 2008, the Food and Drug
Administration (FDA) reported more than 1000 unexpected
and severe adverse events, mostly associated with transvagi-
nal placement of surgical mesh to treat pelvic organ prolapse
(POP) and stress urinary incontinence (SUI). In 2011 and
2012, second and third FDA amendments were questioning
the role of mesh application for POP and SUI repair and
proposing a change to Class III status that would allow the
request of premarket approval and postmarket surveillance
studies [2]. A minority of patients (less than 5% according to
Manufacturer and User Facility Device Experience MAUDE
database) suffered from the complications but due to partly
severe course and rising public interest the trend for mesh
application stopped. Meanwhile, manufacturers in USA are
confronted with >100 000 lawsuits. The allegations of the
manufacturers are still severe. The companies are accused
of misleading. The plaintiffs claim that it is “the legal duty
of the manufacturers to ensure the efficacy and safety of
transvaginal meshes,” but instead they provide patients with
“false and misleading information about the efficacy and
safety of products.” Several mesh products were withdrawn
from themarket.Themajority of manufacturers are expected
to compromise quickly with the plaintiffs, threatened by
the numerous lawsuits and the bad course of the so-called
“Bellwether Trials” for the industry.
Due to reported complications and consecutive law issues
especially in USA there is a high uncertainty among clini-
cians and patients about the application of urogynecologic
implants. New regulation strategies are urgent and in debate
now.
There is a lack of appropriate preclinical tests and research
on the risks of surgical meshes for use in female pelvic floor.
However, what do we know by now? Tension-free vaginal
tape (TVT) developed as a gold standard for the treatment
of female SUI with good long-term functional results of 87%
after 17 yrs of follow-up [3]; similar results were found for
midterm follow-up of TOT (transobturator tape). Various
single incision slings for female SUI and male slings are used
for over 10 years but there is still a lack of good scientific
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Table 1: IDEAL stages (Dahm et al., 2014) [11].
Phase Type of urologistinvolved Purpose (study design)
Idea (1) Very few, innovators Proof of concept (structured case reports)
Development (2a) Few, innovators andearly adopters Procedure development (prospective development studies)
Exploration (2b) Many, early adoptersand early majority
Refinement, community learning and consensus, and learning curve evaluation
(preliminary collaborative cohort studies building toward randomized trials)
Assessment (3) Many, early majority Formal comparison of benefits and short-term safety (randomized controlled trials)
Long-term follow-up
(4) All eligible Surveillance, quality assurance, and long-term safety (registry)
data. In particular, there is a lack of knowledge to identify
patients at high risk for mesh related complications, in which
the risk benefit ratio is not balanced. Indication for pelvic
floor devices should be focused on patients with low risk for
mesh complications and high risk for failure of mesh-free
procedures.
Artificial urinary sphincter is a gold standard therapy
for severe male SUI but complete numbers of explanations
(about 30%) and other complications are still missing. The
current Cochrane Review included 19 randomised trials
of anterior vaginal wall prolapse and found no significant
differences for subjective postoperative outcome and quality
of life, de novo dyspareunia, SUI, and reoperations with
or without mesh-assisted reconstruction. Better anatomical
results but more reoperations due to mesh erosions (10%)
were found in themesh-group [4].The erosions are associated
with other complications, as infections, bleedings, or chronic
pain due to nerve lesions. The most severe complications
include organ perforations, massive bleeding, and sepsis.
Long-time complications are scarring and shortening of the
vagina and recurrent POP and/or SUI.
What is the future for the use of alloplastic material for
pelvic floor reconstruction?
Surgeons should perform surgery for SUI or POP only if
they are adequately trained in this subspecialist area and are
aware of all potential therapeutic options and complications.
The surgeon experienced in the technique has less complica-
tions than less experienced surgeons [5].
The proper education of the patient is an obligation prior
to operation. The pros and cons should be outlined for each
patient prior to final selection of a surgical technique. Patients
should be evaluated for risk factors and in case of recurrence
the reasons for unsuccessful initial treatment and the feasi-
bility of repeated surgical treatment should be evaluated [6].
The indications formeshes should be restricted to high-grade
or recurrent prolapse, additional risk factors (obesity, lung
emphysema, prolapse of multiple compartments, enterocele,
and cystocele with lateral fascia defect). Postoperative control
of results is important. A PF- (pelvic floor-) sonography
is a very useful tool to control the mesh position. In case
of complications or recurrence strategies mesh removal can
be evolved based on PF-sonography [7]. Specialised centers
should be consulted in case of complications; mesh removal
is often a surgical challenge and can be associated with severe
injuries and complications.
Material features like biocompatibility are crucial factors
for foreign body reaction and ingrowth of the material. New
studies for materials showed less complications if a type
1 mesh was used (monofilament, macroporous, and light-
weighted) [8]. Further basic research studies on material
features are important [9].
Finally, a structured development process and long-term
registers for the implants are needed in order to provide
better patient counselling and to promote technological
improvements of alloplastic materials.
The current scientific framework, based largely on uncon-
trolled case series, does not serve patients well and has no
future. In an era of comparative effectiveness, much stronger
evidence and possibly cost-utility studies will be needed
to evaluate treatment benefits and harms of the surgical
therapies with the application of alloplastic materials.
In 2009, the Lancet dedicated a series to the topic of
“Surgical Innovation and Evaluation” and its current status. A
5-stage description of the surgical development process was
proposed, the so-called IDEAL model (innovation, develop-
ment, exploration, assessment, and long-term study), which
allows assigning every surgical innovation to its particular
corresponding step of development (Table 1) [10, 11].
After the specification of the recommendations concern-
ing IDEAL to the field of urology, several scientific groups
utilized the IDEAL model of surgical innovation in the
development of a novel surgical technique in order to show
how surgical research may be concluded when strictly driven
following standardized recommendations [11, 12].
A last stage of IDEAL requires long-term safety studies
and registers. Up to date only a small number of implanted
materials are evaluated in clinical trials. To provide the quality
assurance of the medical products it is urgent to create
national and international registers.
Such registers are already established by surgeons for
inguinal and abdominal hernia repair (i.e., EuraHs) [13].
This knowledge could be implemented for the purpose of
urogynecology by establishing a specialised implant register.
The register would open the possibility to gain high quality
results on indications, complications, and individual deci-
sions concerning surgical methods and choice of material.
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Central registers are therefore the future instrument to
provide the surgeon in a cost-effective and timely manner
with the information for a responsible and individualized
preoperative selection of the product.
The surgical procedures and the implementation of new
techniques should be evaluated in consideration of human
rights network and bioethical aspects. The Hippocratic oath
“first do not harm” is a challenge in urogynecology and
should lead every therapeutic decision.
We hope that the readers of this journal will find in this
special issue not only accurate data and updated reviews on
the recent development and indications for mesh application
for POP and SUI but also the answer to such important
questions as immunological and inflammatory reactions on
the implantation of alloplastic materials and their impact on
the biocompatibility in the host, latest imaging and other
technologies for clinical evaluation and advances in biocom-
patibility of implants, next generation implants, strategies for
clinical evaluation, and long-term surveillance of alloplastic
materials (IDEAL).
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